Graft loss among renal-transplant recipients with early reduction of immunosuppression for BK viremia

被引:0
|
作者
Marwan M Azar [1 ,2 ]
Roland Assi [3 ]
Aziz K Valika
David B Banach [4 ]
Isaac E Hall [5 ]
Marie-Louise Landry [6 ]
Maricar F Malinis [2 ,3 ]
机构
[1] Department of Pathology,Section of Micro-biology,Massachusetts General Hospital
[2] Section of Infectious Dis-eases,Yale School of Medicine
[3] Department of Surgery,Yale University School of Medicine
[4] Division of Infectious Diseases,University of Connecticut School of Medicine  5. Division of Hypertension and Nephrology,University of Utah School of Medicine 
关键词
BK virus; Renal transplant; Screening; PyVAN; Prevention; Graft loss;
D O I
暂无
中图分类号
R699.2 [肾脏手术];
学科分类号
1002 ; 100210 ;
摘要
AIM To review the incidence of graft loss and acute rejection among renal transplant recipients with early reduction of immunosuppression for BK viremia.METHODS We performed a retrospective analysis of consecutive de-novo kidney-only transplants from January 2009 to December 2012 to evaluate the incidence of Polyomavirus associated nephropathy(PyV AN). Recipient plasma was screened for BKV DNA via quantitative polymerase chain reaction(PCR) at months 1,3,6,9 and 12 post-transplant and on worsening graft function.Immunosuppression was reduced at ≥ 3-log copies/mL. Those with viremia of ≥ 4-log copies/mL(presumptive PyV AN) underwent renal transplant biopsy. Presumptive Py VAN(PP) and definitive Py VAN(DP; biopsy-proven) were treated by immunosuppression reduction(IR) only. RESULTS Among 319 kidney transplant recipients,the median age was 53 years(range 19-83),65.8% were male,and 58.9% were white. Biopsy-proven acute rejection was found in 18.5% within 0-168 wk. Death-censored graft loss occurred in 5.3%(n = 17) and graft loss attributable to PyV AN was 0.6%(n = 2). Forty-seven patients were diagnosed with PP(14.7%) and 18(5.6%) with DP. Graft loss among participants with PyV AN(8.5%) and those without(4.8%) was not significantly different. Deceased donor kidney transplantation(OR = 2.3,95%CI = 1.1-4.6) and AR(OR = 2.3,95%CI = 1.2-4.7) were associated with Py VAN in the multivariate analysis. BK viremia between 3 and 4-log copies/mL occurred in 27 patients,all of whom underwent IR. Of these,16(59%) never developed PyV AN while 11(41%) developed PyV AN(4 DP,7 PP) within a range of 11-39 wk. CONCLUSION Instituting an early reduction of immunosuppression,in the absence of adjunctive antivirals,is effective at preventing PyV AN and may be associated with a lower incidence of graft-loss without a reciprocal increase in the incidence of acute rejection.
引用
收藏
页码:269 / 275
页数:7
相关论文
共 50 条
  • [41] BK PAPOVAVIRUS INFECTIONS IN RENAL-TRANSPLANT RECIPIENTS - CONTRIBUTION OF DONOR KIDNEYS
    ANDREWS, C
    SHAH, KV
    RUBIN, R
    HIRSCH, M
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1982, 145 (02): : 276 - 276
  • [42] RENAL-TRANSPLANT IMMUNITY AND IMMUNOSUPPRESSION
    MCENERY, PT
    FINE, R
    ASCHER, N
    ETTENGER, R
    CONLEY, S
    FRIEDMAN, J
    TEJANI, A
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1986, 7 (04) : 312 - 317
  • [43] Early Tacrolimus Exposure Is Associated With BK-Viremia in Kidney Transplant Recipients
    Meziyerh, Soufian
    van Rijn, Aline L.
    van der Helm, Danny
    van Gelder, Teun
    van der Boog, Paul J. M.
    Kroes, Aloysius C. M.
    de Fijter, Johan W.
    Moes, Dirk Jan A. R.
    Rotmans, Joris I.
    Feltkamp, Mariet C.
    de Vries, Aiko P. J.
    [J]. TRANSPLANTATION, 2022, 106 (09) : S199 - S199
  • [44] ADRENAL RESERVE IN RENAL-TRANSPLANT RECIPIENTS WITH CYCLOSPORINE, AZATHIOPRINE, AND PREDNISONE IMMUNOSUPPRESSION
    SHAPIRO, R
    CARROLL, PB
    TZAKIS, AG
    CEMAJ, S
    LOPATIN, WB
    NAKAZATO, P
    [J]. TRANSPLANTATION, 1990, 49 (05) : 1011 - 1013
  • [45] Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients
    Almeras, C.
    Vetromile, F.
    Garrigue, V.
    Szwarc, I.
    Foulongne, V.
    Mourad, G.
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2011, 13 (02) : 101 - 108
  • [46] Monitoring of polyomavirus BK replication and impact of preemptive immunosuppression reduction in renal-transplant recipients in China: a 5-year single-center analysis
    Huang, Gang
    Wang, Chang-xi
    Zhang, Lei
    Fei, Ji-guang
    Deng, Su-xiong
    Qiu, Jiang
    Li, Jun
    Chen, Guo-dong
    Chen, Li-zhong
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2015, 81 (01) : 21 - 26
  • [47] Screening for BK Viremia/Viruria and the Impact o Management of BK Virus Nephropathy in Renal Transplant Recipients
    Zakaria, Zakaria E.
    Elokely, Amir M.
    Ghorab, Adel A.
    Bakr, Adel, I
    Halim, Medhat A.
    Gheith, Osama A.
    Nagib, Ayman M.
    Makkeyah, Yahya
    Balaha, Mohamed A.
    Magdy, Mahmoud M.
    Al-Otaibi, Torki
    [J]. EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2019, 17 : 83 - 91
  • [48] Impact of Age and Race on BK Viremia among Kidney Transplant Recipients.
    Mehta, S.
    Ali, N.
    Lonze, B.
    Stachel, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 837 - 837
  • [49] Efficacy of Intravenous lmmunoglobulin in the Treatment of Persistent BK Viremia and BK Virus Nephropathy in Renal Transplant Recipients
    Vu, D.
    Shah, T.
    Ansari, J.
    Naraghi, R.
    Min, D.
    [J]. TRANSPLANTATION PROCEEDINGS, 2015, 47 (02) : 394 - 398
  • [50] PARATHYROIDECTOMY (PTE) + GRAFT DYSFUNCTION IN RENAL-TRANSPLANT (TP) RECIPIENTS
    SURANYI, MG
    HAWLEY, C
    RIGBY, R
    HARTLEY, L
    PETRIE, J
    BURKE, J
    HARDIE, I
    [J]. KIDNEY INTERNATIONAL, 1992, 42 (04) : 1048 - 1048